Cost-effectiveness analysis of three kinds of nucleoside analogues for chronic hepatitis B

LIN Jing-shi

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To investigate economic effects of three kinds of nucleoside analogues in treatment of chronic hepatitis B. Methods 268 cases were divided into three groups, ADV group with adefovir dipivoxil 10mg, ETV group with entecavir 0.5 mg, LdT group with telbivudine 600 mg. All the groups were administered once a day with a course of 48 weeks. Efficacy and adverse reactions were observed. Cost-effectiveness analysis was used. Results ETV group and LdT group were better than ADV group in terms of HBV-DNA negative conversion rate(P<0.01),in HBeAg negative conversion rate and ALT normalization rate, three groups showed no statistically significant differences(P>0.05), The adverse reactions of three groups had no significant difference(P>0.05).The effectiveness ratio of ADV group, ETV group, LdT group was 115.38, 156.51, 96.98 respectively.Telbivudine was superior to adefovir dipivoxil and entecavir in terms of economics. Conclution Telbivudine group was the optimal solution for chronic hepatitis B.

Cost-effectiveness analysis of three kinds of nucleoside analogues for chronic hepatitis B

Wenling First People's Hospital of Zhejiang Province, Wenlin 317500, China

Received Date: 2011-05-29

Rev Recd Date: 2011-07-22

Key words:

Abstract: Objective To investigate economic effects of three kinds of nucleoside analogues in treatment of chronic hepatitis B. Methods 268 cases were divided into three groups, ADV group with adefovir dipivoxil 10mg, ETV group with entecavir 0.5 mg, LdT group with telbivudine 600 mg. All the groups were administered once a day with a course of 48 weeks. Efficacy and adverse reactions were observed. Cost-effectiveness analysis was used. Results ETV group and LdT group were better than ADV group in terms of HBV-DNA negative conversion rate(P<0.01),in HBeAg negative conversion rate and ALT normalization rate, three groups showed no statistically significant differences(P>0.05), The adverse reactions of three groups had no significant difference(P>0.05).The effectiveness ratio of ADV group, ETV group, LdT group was 115.38, 156.51, 96.98 respectively.Telbivudine was superior to adefovir dipivoxil and entecavir in terms of economics. Conclution Telbivudine group was the optimal solution for chronic hepatitis B.

HTML

Reference (10)

[1]	Rehermann B,Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infextion[J]. Nat Rev lmmunol,2005,5(3):215.
[2]	Lu FM, Zhuang H. Management of hepatitis B in China[J].Chin Med J, 2009,122(1): 3.
[3]	Choe WH, Hong SP, Kim BK, et al.Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir[J].Antivir Ther. 2009, 14(7):985.
[4]	中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881.
[5]	陈洁. 药物经济学[M]. 第3版. 成都:成都科技大学出版社,2000:97.
[6]	艾伟鹏,方红成. 三种他汀类药物治疗高脂血症的经济学分析[J].现代医药卫生,2005,21(10):1200.
[7]	孔晓东.药物经济学:概念、方法和应用[J].国外医学药学分册,1994,21(1):16.
[8]	Lok ASF,McMahon BJ. AASLD practice guidelines: Chronic hepatitis B[J]. Hepatology,2007,45(2):507.
[9]	Chang TT, Jia JD, Omata M,et al. New therapies for chronic hepatitis B infection[J]. Liver International,2006 26(suppl2):30.
[10]	Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B[J]. Ther Clin Risk Manag,2009,5(10):789.

Message Board

Cost-effectiveness analysis of three kinds of nucleoside analogues for chronic hepatitis B

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views